As young people age out of their pediatric or adolescent HIV care and treatment programs, they require different types of support. However, there is a lack of understanding and planning for potential transitions in care for young people in most countries. As a result, HP+ created the Pediatric HIV Transition Model to inform target setting, forecasting, and planning for young people’s transitions in care in PEPFAR-supported countries. This model projects the number of children, adolescents, and young adults ages 0-24 on antiretroviral therapy (ART) who are eligible for transitions in care and switching to tenofovir/lamivudine/dolutegravir (TLD) or another newly-introduced regimen. Users can develop up to three scenarios for ART coverage projections and results are disaggregated by subnational unit, gender, and single-year age band.
Health Policy Plus. 2018. Pediatric HIV Transition Model. Washington, DC: Palladium, Health Policy Plus.
English XLSX 3639.4 kbNovember 2018
Health Policy Plus. 2018. Pediatric HIV Transition Model: User’s Guide. Washington, DC: Palladium, Health Policy Plus.
English PDF 734.0 kbNovember 2018
Information presented on this website is considered public information and may be distributed or copied freely unless identified as being subject to copyright protection.